Open AccessMYCOPHENOLATE MOFETIL DECREASES ENDOTHELIAL PROSTAGLANDIN E 2 IN RESPONSE TO ALLOGENEIC T CELLS OR CYTOKINES1
Author(s) -
Roman A. Blaheta,
Karen Nelson,
Elsie Oppermann,
Kerstin Leckel,
Sebastian Harder,
Jindřich Činátl,
Stephan Weber,
Maria Shipkova,
A. Encke,
B. H. Markus
Publication year - 2000
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/00007890-200005150-00044
Subject(s) - mycophenolate , prostaglandin e2 , tacrolimus , mycophenolic acid , immune system , pharmacology , transplant rejection , mixed lymphocyte reaction , immunosuppressive drug , transplantation , cd8 , immunology , cytokine , chemistry , medicine , t cell , endocrinology
Prostaglandin E2 (PGE2) is a powerful endogenous immune suppressant and interferes with various T-cell functions. However, it is not known in detail whether immunosuppressive drugs influence the PGE2-driven immune response in transplant patients. Therefore, we investigated the effect of several immunosuppressive compounds, in particular the novel drug mycophenolate mofetil (MMF), on endothelial PGE2 release.